A range of humoral related adverse events can occur after treatment of haematological malignancy with chimeric antigen receptor cell therapies. Here the authors characterise the persistence of humoral immunity and response to vaccination after patients receive B cell targeted chimeric antigen receptor T cell therapy.
- Stosh Ozog
- Elizabeth M. Krantz
- Joshua A. Hill
